INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ( "Altimmune" or the "Company" ) ALT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm - Novo Nordisk ( NYSE:NVO ) , Altimmune ( NASDAQ:ALT )
NEW YORK, Aug. 16, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Novo Nordisk A/S NVO, Altimmune, Inc. ALT, SelectQuote, Inc.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Aug. 16, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. ALT between August 10, 2023 and June 25, 2025 ( the "Class Period" ) , of the important October 6, 2025 lead plaintiff deadline.
These Analysts Slash Their Forecasts On Altimmune Following Q2 Results - Altimmune ( NASDAQ:ALT )
Altimmune, Inc. ALT posted a loss for the second quarter on Tuesday. The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's quarterly sales came in at $5.000K.
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Altimmune, Inc. ( ALT ) Investors - Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Altimmune ( NASDAQ:ALT )
ATLANTA, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- A shareholder class action lawsuit has been filed Altimmune, Inc. ( "Altimmune" or the "Company" ) ALT. The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, ...
ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - Altimmune ( NASDAQ:ALT )
NEW YORK, Aug. 12, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Altimmune, Inc. ALT between August 10, 2023 and June 25, 2025 ( the "Class Period" ) .
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Altimmune ( NASDAQ:ALT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
Altimmune Q2 FY2025 Earnings Call Transcript - Altimmune ( NASDAQ:ALT )
Altimmune, Inc. ALT reported its second-quarter financial results before Tuesday's opening bell. Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a ...
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm - Altimmune ( NASDAQ:ALT )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune ( ALT ) To Contact Him Directly To Discuss Their Options
Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ( "Altimmune" or the "Company" ) ALT of a class action securities lawsuit.
Altimmune Board of Directors Appoints Jerry Durso as Chairman - Altimmune ( NASDAQ:ALT )
Appointment recognizes Mr. Durso's extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc.
Altimmune Board of Directors Appoints Jerry Durso as Chairman
Appointment recognizes Mr. Durso's extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH ...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune Lawsuit - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ( "Altimmune" or the "Company" ) ALT of a class action securities lawsuit.
Altimmune, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 6, 2025 Deadline to file Lead Plaintiff Motion. - Altimmune ( NASDAQ:ALT )
Investors can contact the law firm at no cost to learn more about recovering their losses
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Altimmune ( NASDAQ:ALT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options.
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Altimmune, Inc. ( ALT ) - Altimmune ( NASDAQ:ALT )
NEW YORK, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of all persons or entities who purchased the securities of Altimmune, Inc. ( ...
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
GAITHERSBURG, Md., Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ( Nasdaq: ALT ) , a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025.
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 - Altimmune ( NASDAQ:ALT )
GAITHERSBURG, Md., Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ALT, a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ( "Altimmune" or the "Company" ) ALT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - BitMine Immersion Techs ( AMEX:BMNR ) , Altimmune ( NASDAQ:ALT )
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday. Shares of Methode Electronics, Inc. MEI fell sharply in today's pre-market trading after the company reported a fourth-quarter adjusted EPS miss.
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease ( ALD )
GAITHERSBURG, Md., July 09, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ( Nasdaq: ALT ) , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first patient in the RESTORE Phase ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT - Altimmune ( NASDAQ:ALT )
NEW YORK, July 03, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ( "Altimmune" or the "Company" ) ALT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Bulls And Bears: Nvidia, Micron, HIMS - And Markets Soar On Mideast And Tariff Relief Bulls And Bears: Nvidia, Micron, HIMS - And Markets Soar On Mideast And Tariff Relief - Altimmune ( NASDAQ:ALT ) , AST SpaceMobile ( NASDAQ:ASTS )
Benzinga examined the prospects for many investors' favorite stocks over the last week - here's a look at some of our top stories. Wall Street surged this week as easing geopolitics and a potential pause in U.S.-China tariffs lifted sentiment.
Altimmune's Fatty Liver Candidate Faces Differentiation Doubts - Altimmune ( NASDAQ:ALT )
Trucchio maintains Buy rating, sees $12 upside on positive 48-week fibrosis readout. William Blair flags underwhelming 24-week data, sees limited 48-week improvement potential. Geopolitical tensions, Fed uncertainty, and fast-moving headlines are driving July volatility.
INVESTOR ALERT: Investigation of Altimmune, Inc. ( ALT ) Announced by Holzer & Holzer, LLC - Altimmune ( NASDAQ:ALT )
ATLANTA, June 26, 2025 ( GLOBE NEWSWIRE ) -- Holzer & Holzer, LLC is investigating whether Altimmune, Inc. ( "Altimmune" or the "Company" ) ALT complied with federal securities laws.
Crude Oil Gains Over 1%; Walgreens Posts Upbeat Earnings - Altimmune ( NASDAQ:ALT ) , Ascent Solar Technologies ( NASDAQ:ASTI )
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday. The Dow traded up 0.82% to 43,335.29 while the NASDAQ gained 0.69% to 20,110.81. The S&P 500 also rose, gaining, 0.66% to 6,132.29. Materials shares jumped by 0.9% on Thursday.
Altimmune Stock Sinks After Mid-Stage Data From Fatty Liver Candidate - Altimmune ( NASDAQ:ALT )
Pemvidutide 1.2 mg and 1.8 mg led to MASH resolution in 59.1% and 52.1% of patients vs. 19.1% with placebo ( p<0.0001 ) . Liver fat reduction reached 58.0% and 62.8% with pemvidutide vs. 16.2% in placebo; weight loss was 5.0% and 6.2% vs. 1.0%.
Dow Surges 200 Points; US GDP Contracts 0.5% - Altimmune ( NASDAQ:ALT ) , Ascent Solar Technologies ( NASDAQ:ASTI )
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.49% to 43,192.54 while the NASDAQ gained 0.36% to 20,045.46. The S&P 500 also rose, gaining, 0.38% to 6,115.14.
Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Altimmune ( NASDAQ:ALT ) , Bit Digital ( NASDAQ:BTBT )
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday. Shares of Altimmune, Inc. ALT fell sharply in today's pre-market trading after the company announced topline results from the IMPACT Phase 2b trial of Pemvidutide in the treatment of MASH.
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks ...
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T. Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Eli Lilly ( NYSE: LLY ) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help patients with diabetes and weight loss.
Biodefense Market is expected to generate a revenue of USD 32.48 Billion by 2030, Globally, at 8.49% CAGR: Verified Market Research®
Lewes, Delaware, June 17, 2025 ( GLOBE NEWSWIRE ) -- The Global Biodefense Market Size is projected to grow at a CAGR of 8.49% from 2023 to 2030, according to a new report published by Verified Market Research®.
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions - Altimmune ( NASDAQ:ALT )
GAITHERSBURG, Md., June 13, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc.
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions
GAITHERSBURG, Md., June 13, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ( Nasdaq: ALT ) , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on ...
Altimmune ( ALT ) Stock Rises Amid Clinical Trial Progress: What's Going On? - Altimmune ( NASDAQ:ALT )
Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and upcoming MASH results may be fueling excitement. Beat the market with ready-to-go trades and pro tools-now 60% off for Memorial Day.
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder ( AUD ) - Altimmune ( NASDAQ:ALT )
GAITHERSBURG, Md., May 19, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc.
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder ( AUD )
GAITHERSBURG, Md., May 19, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ( Nasdaq: ALT ) , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase ...
Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
Bad news keeps coming for Novo Nordisk ( NYSE: NVO ) . The Denmark-based drugmaker's share price has plunged roughly 55% below its high set last summer. Earlier this week, a study published in The New England Journal of Medicine revealed that patients taking Eli Lilly's Zepbound lost more weight ...
Altimmune to Participate at Two Upcoming Investor Conferences - Altimmune ( NASDAQ:ALT )
GAITHERSBURG, Md., May 14, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ALT, a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be ...
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital - Altimmune ( NASDAQ:ALT ) , Hercules Capital ( NYSE:HTGC )
GAITHERSBURG, Md., May 13, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ALT, a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc.
Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings?
KEYS is expected to report year-over-year revenue growth in the second quarter of fiscal 2025, driven by healthy demand across both segments.
Doximity Q4 Earnings Likely to Reflect Strong Product Momentum
Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.
How Much Upside is Left in Altimmune ( ALT ) ? Wall Street Analysts Think 285.86%
The mean of analysts' price targets for Altimmune (ALT) points to a 285.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ - Altimmune ( NASDAQ:ALT )
GAITHERSBURG, Md., May 08, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ALT, a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced the presentation of new analyses at the European Association for ...
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 - Altimmune ( NASDAQ:ALT )
GAITHERSBURG, Md., May 06, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ALT, a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025.
What's Going On With Altimmune ( ALT ) Stock Today? - Altimmune ( NASDAQ:ALT )
The stock is higher ahead of next week's presentation at the European Association for the Study of the Liver International Liver Congress. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in volatile markets.
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025 - Altimmune ( NASDAQ:ALT )
GAITHERSBURG, Md., May 01, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc.
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
GAITHERSBURG, Md., May 01, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ( Nasdaq: ALT ) , a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the Company will present analyses of ...
